• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by AVROBIO Inc.

    7/24/23 3:23:27 PM ET
    $AVRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AVRO alert in real time by email
    SC 13G 1 doc1.htm NONE Schedule 13G


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. n/a )*
     
    AVROBIO, Inc. 

    (Name of Issuer)
     
    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     
    05455M100

    (CUSIP Number)
     
    July 13, 2023

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         o  Rule 13d-1(b)
     
         x  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  05455M100      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     BML Investment Partners, L.P.
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   o
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Delaware
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     0
       
    6 SHARED VOTING POWER
      
     3545396
       
    7 SOLE DISPOSITIVE POWER
      
     0
       
    8 SHARED DISPOSITIVE POWER
      
     3545396
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     3545396
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     8.0%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     PN
     

    FOOTNOTES
      
     BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
     
     

     
     
    CUSIP No.  05455M100      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     Braden M Leonard
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   x
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     United States
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     420000
       
    6 SHARED VOTING POWER
      
     3545396
       
    7 SOLE DISPOSITIVE POWER
      
     420000
       
    8 SHARED DISPOSITIVE POWER
      
     3545396
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     3965396
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     9.0%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     IN
     

    FOOTNOTES
      
     BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
     
     

     
     
    Item 1.

     
    (a)
    Name of Issuer
     
     
    AVROBIO, Inc.

     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    100 Technology Square, Sixth Floor, Cambridge, MA 02139

    Item 2.

     
    (a)
    Name of Person Filing
     
     
    BML Investment Partners, L.P.

     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    65 E Cedar, Suite 2
    Zionsville, IN 46077

     
    (c)
    Citizenship
     
     
    Delaware

     
    (d)
    Title of Class of Securities
     
     
    Common Stock, par value $0.0001 per share

     
    (e)
    CUSIP Number
     
     
    05455M100

     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     
    (g)
    o
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned: 3,965,396

     
    (b)
    Percent of class: 9.0%

     
    (c)
    Number of shares as to which the person has:

     
    (i)
    Sole power to vote or to direct the vote: 420,000

     
    (ii)
    Shared power to vote or to direct the vote: 3,965,396

     
    (iii)
    Sole power to dispose or to direct the disposition of: 420,000

     
    (iv)
    Shared power to dispose or to direct the disposition of: 3,965,396

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .
     
    N/A
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    N/A
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    N/A
     
    Item 8.
    Identification and Classification of Members of the Group
     
    N/A
     
    Item 9.
    Notice of Dissolution of Group
     
    N/A
     
     
     

     
     
     
    Item 10.
    Certification
      
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
     BML Capital Management, LLC
     
        
    Date: July 24, 2023
    By:
    /s/  Braden M Leonard 
       Name: Braden M Leonard 
       Title:  Managing Member 
        
     
     
     
      
        
    Date: July 24, 2023
    By:
    /s/  Braden M Leonard 
       Name: Braden M Leonard 
       
        
     
    Footnotes:
    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M.Leonard. As a result, Braden M.Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b) (1) of the Exchange Act.

    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     


    Get the next $AVRO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AVRO

    DatePrice TargetRatingAnalyst
    12/18/2023Buy → Neutral
    Mizuho
    1/6/2022$28.00 → $6.00Buy
    Mizuho
    1/5/2022$22.00 → $6.00Overweight
    Barclays
    1/5/2022$7.00 → $3.00Equal-Weight
    Morgan Stanley
    1/5/2022Buy → Neutral
    BTIG
    1/5/2022$28.00 → $8.00Buy
    Needham
    11/19/2021$24.00 → $7.00Overweight → Equal-Weight
    Morgan Stanley
    10/12/2021$27.00 → $25.00Overweight
    Morgan Stanley
    More analyst ratings

    $AVRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer

      Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. "Dan is an experienced public-company CFO who will add significant financial expertise to our team," said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. "With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer." Dan brings with him a wealth of knowledge in corporate finance, business str

      6/3/24 4:15:00 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure

      Study to evaluate TX45 impact on cardiopulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension, a patient population in urgent need of novel therapies TX45 clinical program advancing on track based on promising initial Phase 1A data; confirmatory Phase 1A data expected mid-2024 and topline Phase 1B data expected in 2025 Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced the initiation of enrollment in the Phase 1B study for TX45, an investigational long-acting relaxin-Fc fu

      3/26/24 7:06:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces Participation at Investor Conferences in March

      Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March: TD Cowen 44th Annual Health Care Conference being held in Boston on March 4 – 6 Leerink Partners Global Biopharma Conference being held in Miami on March 11 – 13 The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink rep

      2/27/24 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    SEC Filings

    See more
    • AVROBIO Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

      6/25/24 9:52:20 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Leadership Update, Entry into a Material Definitive Agreement, Changes in Registrant's Certifying Accountant, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Control of Registrant

      8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

      6/20/24 4:25:03 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form 8-K/A filed by AVROBIO Inc.

      8-K/A - AVROBIO, Inc. (0001681087) (Filer)

      6/18/24 11:51:59 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AVROBIO downgraded by Mizuho

      Mizuho downgraded AVROBIO from Buy to Neutral

      12/18/23 8:06:56 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mizuho reiterated coverage on Avrobio with a new price target

      Mizuho reiterated coverage of Avrobio with a rating of Buy and set a new price target of $6.00 from $28.00 previously

      1/6/22 6:59:42 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays reiterated coverage on Avrobio with a new price target

      Barclays reiterated coverage of Avrobio with a rating of Overweight and set a new price target of $6.00 from $22.00 previously

      1/5/22 9:51:19 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Former 10% owner of AVROBIO Leonard Braden Michael acquired 433,688 shares (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      6/25/24 1:42:11 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Donenberg Phillip B.

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      6/24/24 4:37:33 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Vitorovic Stefan was granted 1,028,674 shares (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      6/24/24 4:35:35 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Leonard Braden Michael bought $971,493 worth of shares (766,635 units at $1.27) (SEC Form 4)

      4 - AVROBIO, Inc. (0001681087) (Issuer)

      5/15/24 11:21:34 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Financials

    Live finance-specific insights

    See more
    • AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

      Provided interim data at WORLDSymposium™ 2022 that showed sustained engraftment across first three patients 1+ year post-gene therapy in Phase 1/2 clinical triali for cystinosis; all remain off oral cysteamine to date Interim clinical data update of AVR-RD-02 in Gaucher disease type 1 planned for 2022; third patient dosed in Phase 1/2 clinical trial Regulatory interactions planned in 2022 to inform clinical development and registration strategies for programs in Gaucher disease, cystinosis, Hunter syndrome and Pompe disease Strong balance sheet with cash runway into Q1 2024 AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a li

      3/17/22 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

      Sustained engraftment observed across first three patients 1+ year post-gene therapy; all remain off oral cysteamine to date Reduction in number of cystine crystals as measured in skin and intestinal mucosa biopsies observed across first three patients Continued favorable safety profile with no adverse events related to drug product to date Clinical proof-of-concept in adult patients lays groundwork for AVROBIO-sponsored trial planned to begin in 2023 Analyst and investor conference call scheduled for today at 8:00 a.m. ET AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported

      2/9/22 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022

      Analyst and investor conference call scheduled for Wednesday, Feb. 9, 2022, at 8:00 a.m. ET Five platform presentations and three posters on the company's clinical and preclinical programs for lysosomal disorders are scheduled throughout the symposium AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposium™ in San Diego, Calif. Additionally, preclinical data from its Pompe disease and Hunter syndrome programs, as we

      1/27/22 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer

      Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. "Dan is an experienced public-company CFO who will add significant financial expertise to our team," said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. "With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer." Dan brings with him a wealth of knowledge in corporate finance, business str

      6/3/24 4:15:00 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO and Tectonic Therapeutic Announce Merger

      Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic's novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments with new and existing leading life sciences investors in connection with merger Combined company expected to have approximately $165 million in cash and cash equivalents at close to provide cash runway into mid-2027 Funding is expected to advance lead asset TX45, a potential best-in-class Fc-relaxin fusion protein, through multiple clinical data catalysts Tectonic's first two programs address indications with high unmet need and no approved therapies Companies to host joint webcast to

      1/30/24 8:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update

      On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provide clinical and regulatory updates on cystinosis program in conjunction with ASGCT annual meeting in May 2023; plan to initiate late-stage cystinosis clinical trial activities in second half 2023, subject to regulatory alignment Collaborator-sponsored Phase 1/2 clinical trial for mucopolysaccharidosis type II (MPS-II), or Hunter syndrome, initiated Announced appointment of current CFO Erik Ostrowski as interim CEO AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a l

      5/11/23 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by AVROBIO Inc.

      SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      6/26/24 8:00:02 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by AVROBIO Inc.

      SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      6/25/24 4:23:25 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by AVROBIO Inc. (Amendment)

      SC 13G/A - AVROBIO, Inc. (0001681087) (Subject)

      5/21/24 10:01:24 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care